The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-11 2022 | The use of bendamustine-rituximab in WM and the impact of dose intensity on patient outcomes
Suzanne Arulogun, MBBS, FRACP, FRCPA, University College London Hospitals NHS Foundation Trust, London, UK, shares the results of a retrospective cohort analysis which evaluated the impact of bendamustine-rituximab (BR) dose intensity on the outcomes of patients with Waldenström’s macroglobulinemia (WM). Results indicated that patients receiving a higher dose of BR demonstrated an improved progression-free survival (PFS), and Dr Arulogun further highlights the implications of these findings. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
